Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 0.5 mg - alprazolam - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 1 mg - alprazolam - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 0.25 mg - alprazolam - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 0.25 mg - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 0.5 mg - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 1 mg - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - palivizumab - respiratory syncytial virus infections - immune sera and immunoglobulins, - synagis is indicated for the prevention of serious lower-respiratory-tract disease requiring hospitalisation caused by respiratory syncytial virus (rsv) in children at high risk for rsv disease:children born at 35 weeks of gestation or less and less than six months of age at the onset of the rsv season;children less than two years of age and requiring treatment for bronchopulmonary dysplasia within the last six months;children less than two years of age and with haemodynamically significant congenital heart disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - palivizumab, quantity: 100 mg - injection, solution - excipient ingredients: histidine; glycine; water for injections - synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in children at high risk of rsv disease. safety and efficacy were established in children with bronchopulmonary dysplasia (bpd), infants with a history of prematurity (gestational age less than or equal to 35 weeks at birth) and children with haemodynamically significant congenital heart disease (chd). (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - palivizumab, quantity: 50 mg - injection, solution - excipient ingredients: histidine; glycine; water for injections - synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in children at high risk of rsv disease. safety and efficacy were established in children with bronchopulmonary dysplasia (bpd), infants with a history of prematurity (gestational age less than or equal to 35 weeks at birth) and children with haemodynamically significant congenital heart disease (chd). (see clinical trials).

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - palivizumab 100mg (;+overage = 122mg/vial) - injection with diluent - 100 mg - active: palivizumab 100mg (;+overage = 122mg/vial) excipient: glycine histidine mannitol nitrogen transferrin water for injection - synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in children at high risk of rsv disease. safety and efficacy were established in children with bronchopulmonary dysplasia (bpd), infants with a history of prematurity (gestational age < 35 weeks at birth) and children with haemodynamically significant congenital heart disease (chd).